Collagenase clostridium histolyticum

Generic Name: Collagenase clostridium histolyticum

Brand Names: Qwo, Santyl, Xiaflex

Drug Type: Biotech

Chemical Formula: -

CAS Number: 9001-12-1

Unique Ingredient Identifier: 9X7O8V25IT

Background: Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers.
...

Indication: Collagenase clostridium histolyticum is indicated for the treatment of adults with Dupuytren's contracture with a palpable cord. Additionally, it is used to treat men with Peyronie's disease diagnosed with a penile curvature deformity of at least a 30-degree angle at the beginning of therapy in addition to palpable plaques. Collagenase ointment is used for t...

Associated Conditions: Dupuytren's Contracture of the Hand (Viking's Disease), Peyronie's Disease, Necrotic tissue

Associated Therapies: -

Clinical Trials

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs Collagenase Ointment for Treating Venous Leg Ulcers

MediWound to initiate a controlled, multicenter Phase II clinical study evaluating EscharEx® against collagenase ointment for treating venous leg ulcers (VLUs) in 2025, supporting its Biologics License Application (BLA) and commercialization strategy. The study will involve 45 patients across multiple sites in the U.S. and Europe, with key safety and efficacy endpoints assessed. MediWound has secured R&D collaborations with Solventum and Mölnlycke to enhance trial consistency and patient outcomes.

globenewswire.com

2 months ago

MediWound Announces Phase II Head-to-Head Study Evaluating

MediWound to initiate a controlled, multicenter Phase II clinical study evaluating EscharEx® against collagenase ointment for treating venous leg ulcers (VLUs) in 2025, supporting its Biologics License Application (BLA) and commercialization strategy. The study will involve 45 patients across multiple sites in the U.S. and Europe, with strategic R&D collaborations with Solventum and Mölnlycke to enhance trial consistency and patient outcomes.

marketscreener.com

2 months ago

MediWound Ltd. Announces Phase II Head-To-Head Study Evaluating EscharEx

MediWound to initiate a multicenter Phase II study in 2025 evaluating EscharEx® against collagenase for venous leg ulcers (VLUs), running concurrently with a Phase III trial. The randomized study will enroll 45 patients across the U.S. and Europe, assessing key safety and efficacy endpoints. Strategic R&D collaborations with Solventum and Mölnlycke Health Care will support the trial.

finance.yahoo.com

2 months ago

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs Collagenase Ointment for Venous Leg Ulcers

MediWound to initiate a controlled, multicenter Phase II clinical study evaluating EscharEx® against collagenase ointment for the treatment of venous leg ulcers (VLUs) in 2025, supporting the Biologics License Application (BLA) for EscharEx and strengthening the commercialization strategy. The study will enroll 45 patients across multiple sites in the U.S. and Europe, with strategic R&D collaborations formed with Solventum and Mölnlycke to enhance trial consistency and patient outcomes.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.